Page 3 - சுயாதீனமான தகவல்கள் கண்காணிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AstraZeneca provides positive update on breast cancer drug | 17 February 2021

AstraZeneca provides positive update on breast cancer drug

Data monitoring committeeIndependent data monitoringAstrazeneca plcLon aznAzn lதகவல்கள் கண்காணிப்பு குழுசுயாதீனமான தகவல்கள் கண்காணிப்புலோன் அஸ்ர்அஸ்ர் ல்

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Adaptimmune Therapeutics PLC (NYSE:ADAP) - The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Adaptimmune Therapeutics PLC (NYSE:ADAP) - The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesMereo biopharma groupMerck co incAeterna zentaris incPfizer incInvitae corpAdaptimmune gain on fund stake disclosureY mabs therapeutics incAikido pharma incEuropean commissionTranslational genomics research instituteData monitoring committeeHealth canada interim orderPharma incVeracyte incSciences corporation

BPTH On Steady Path, CGIX On Watch, GLPG/GILD Scrap IPF Drug, REGN s Libtayo Gets FDA Nod

BPTH On Steady Path, Cancer Genetics On Watch, GLPG/GILD Scrap IPF Drug, REGN s Libtayo Gets FDA Nod Read on. 1. Bio-Path On A Steady Path Bio-Path Holdings Inc. (BPTH) has been granted the third U.S. patent, expanding the protection of its DNAbilize platform technology that helps to deliver DNA therapeutics directly to cancer cells. In addition, the company is expected to be issued a patent related to its lead product candidate, Prexigebersen, in combination with either a cytidine analogue, such as decitabine, or the Bcr-Abl tyrosine kinase inhibitors dasatinib and nilotinib, on February 23, 2021. Prexigebersen is in a Phase 2 study for blood cancers and Prexigebersen-A, a drug product modification of Prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors.

Sanofi libtayoRegeneron libtayoZynerba pharmaceuticals incRegeneron pharmaceuticals incGalapagos gilead scrap development of ziritaxestatEnlivex therapeutics ltdData monitoring committeePath holdings incCancer genetics incPanbela therapeutics incAnchiano therapeutics ltdDaily doseCancer geneticSteady pathPath holdingsGenetics on watch

Sputnik V s efficacy in fighting COVID-19 is validated by internationally peer reviewed data published in The Lancet

Sputnik V s efficacy in fighting COVID-19 is validated by internationally peer reviewed data published in The Lancet Sputnik V s efficacy in fighting COVID-19 is validated by internationally peer reviewed data published in The Lancet Russian Direct Investment Fund 1305 Russian Direct Investment Fund 04 February 2021 11:42 In an interim analysis of a Phase III clinical trial, Sputnik V showed strong efficacy, immunogenicity and safety results. Efficacy of Sputnik V against COVID-19 was reported at 91.6%. Analysis included data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.

United kingdomUnited statesRussian federationRepublic of guineaCecil czerkinskyAlexander gintsburgKirill dmitrievHildegundcj ertlDavid livermoreUniversity of east angliaNational institute of healthGamaleya national research centerData monitoring committeeRussian direct investment fundAkm information agencyGamaleya research institute of epidemiology

Sputnik V COVID-19 vaccine shows 91 6 % efficacy in phase 3 trials: Lancet study

Updated Feb 03, 2021 | 08:56 IST Sputnik V is based on a well-studied human adenoviral vectors platform and is the world’s first registered vaccine against coronavirus. Sputnik V COVID-19 vaccine shows 91.6 % efficacy in phase 3 trials: Lancet study Key Highlights Sputnik V shows strong efficacy, immunogenicity and safety results in an interim analysis of a phase 3 clinical trial The level of virus neutralizing antibodies of volunteers vaccinated with Sputnik V is 1.3-1.5 times higher than the level of antibodies of patients who recovered from COVID-19 Sputnik V is one of the three vaccines in the world with efficacy of over 90 per cent

Russian federationAlexander gintsburgKirill dmitrievGamaleya research institute of epidemiologyGamaleya national research centerData monitoring committeeRussian direct investment fundRussian sputnikGamaleya research instituteIndependent data monitoringSputnikv covid 19 vaccineCoronavirus vaccineCovid 19 vaccineGamaleya national research center of epidemiology and microbiologyDr reddy rsquo sரஷ்ய கூட்டமைப்பு